Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
447.7(c) 446.98(c) 450.89(c) 460.72(c) 452.58 Last
788 627 430 964 345 121 609 466 386 727 Volume
+2.91% -0.16% +0.87% +2.18% -1.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2 344 M - -
Net income 2021 206 M - -
Net Debt 2021 336 M - -
P/E ratio 2021 214x
Yield 2021 -
Sales 2022 2 851 M - -
Net income 2022 309 M - -
Net Debt 2022 128 M - -
P/E ratio 2022 146x
Yield 2022 -
Capitalization 43 767 M 43 767 M -
EV / Sales 2021 18,8x
EV / Sales 2022 15,4x
Nbr of Employees 5 500
Free-Float 98,7%
More Financials
Company
DexCom, Inc. specialises in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 78.3% of net sales. 
More about the company
Ratings of DexCom, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about DEXCOM, INC.
07/21DEXCOM : Cowen Analyst Assumes Coverage on Outperform-Rated DexCom, Sets $525 Pr..
MT
07/15DEXCOM : Gets FDA Clearance to Share Glucose Monitoring Data With Third-Party De..
MT
07/15DEXCOM : FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices
BU
07/15FDA Clears DexCom, Inc.'s Real-Time APIs for Third-Party Apps and Devices
CI
07/09DEXCOM : Insider Selling in Dexcom (DXCM) Shares Continues
MT
07/08INSIDER TRENDS : Insider Adds to Selling Trend at Dexcom
MT
07/07DEXCOM : Oppenheimer Adjusts DexCom PT to $500 From $480, Maintains Outperform R..
MT
07/07DEXCOM SCHEDULES SECOND QUARTER 2021 : 30 p.m. Eastern Time
BU
07/07SNC LAVALIN : Dexcom Signs Up SNC-Lavalin for Medical Manufacturing Facility In ..
MT
07/01DEXCOM INC : Other Events (form 8-K)
AQ
06/25DEXCOM : Insiders Make Significant Stock Sales in Dexcom (DXCM) Shares Extending..
MT
06/25DEXCOM : CGM Plays Starring Role at 81st Scientific Sessions of the American Dia..
BU
06/25DEXCOM, INC.(NASDAQGS : DXCM) added to Russell Midcap Growth Index
CI
06/25DEXCOM, INC.(NASDAQGS : DXCM) added to Russell Midcap Index
CI
06/25DEXCOM, INC.(NASDAQGS : DXCM) dropped from Russell Top 200 Growth Index
CI
More news
News in other languages on DEXCOM, INC.
06/22DEXCOM : L'athlète d'endurance Sébastien Sasseville traversera le Canada à vélo ..
06/11DEXCOM : La colombie-britannique est la première province à couvrir le système d..
06/04DEXCOM : explora el futuro de la monitorización continua de la glucosa
06/04DEXCOM : richtet den Blick auf die Zukunft der kontinuierlichen Blutzuckermessun..
06/03DEXCOM : kijkt naar de toekomst van continue glucosemonitoring
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | MarketScreener
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 452,58 $
Average target price 465,81 $
Spread / Average Target 2,92%
EPS Revisions
Managers and Directors
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Jereme M Sylvain SVP-Finance, Chief Financial & Accounting Officer
Andrew K. Balo EVP-Clinical Affairs, Regulatory Strategy
Jacob S. Leach Chief Technology Officer & Executive VP
Shelly R. Selvaraj Senior Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
DEXCOM, INC.24.61%41 618
ABBOTT LABORATORIES10.33%200 283
MEDTRONIC PLC9.73%168 081
BECTON, DICKINSON AND COMPANY0.34%70 145
HOYA CORPORATION5.96%50 251
ALIGN TECHNOLOGY, INC.19.44%48 667